Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment

Reuters

2025/05/26

Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment

SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95667) on May 26, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538808141"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538808141\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538808141?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-26 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538808141","market":"us","top_or_hot":-1,"title":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon <a href=\"https://laohu8.com/S/GCG.UK\">$(GCG.UK)$</a> and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95667) on May 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-26 08:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon <a href=\"https://laohu8.com/S/GCG.UK\">$(GCG.UK)$</a> and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95667) on May 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信達生物","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL3LGflG:1","article_id":"2538808141","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538808141","pubTimestamp":1748217619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire  on May 26, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物","BK1147":"投资银行业与经纪业","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01911":"华兴资本控股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念","BK1589":"北水核心资产","BK1161":"生物科技"},"translate_title":"信达生物Mazdutide在中国成人中突破性3期研究发表于NEJM，标志着肥胖治疗的里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01911":0.9,"01801":0.9},"content_text":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment\n    \n\n        SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95667) on May 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}